Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non-small cell lung cancer patients.
CTCs
NSCLC
PD-L1
cytology imprints
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
03
01
2023
received:
08
11
2022
accepted:
07
03
2023
medline:
8
5
2023
pubmed:
10
3
2023
entrez:
9
3
2023
Statut:
ppublish
Résumé
Alternative sources of tumour information need to be explored in patients with non-small cell lung cancer (NSCLC). Here, we compared programmed cell death ligand 1 (PD-L1) expression on cytology imprints and circulating tumour cells (CTCs) with PD-L1 tumour proportion score (TPS) from immunohistochemistry staining of tumour tissue from patients with NSCLC. We evaluated PD-L1 expression using a PD-L1 antibody (28-8) in representative cytology imprints, and tissue samples from the same tumour. We report good agreement rates on PD-L1 positivity (TPS ≥ 1%) and high PD-L1 expression (TPS ≥ 50%). Considering high PD-L1 expression, cytology imprints showed a PPV of 64% and a NPV of 85%. CTCs were detected in 40% of the patients and 80% of them were PD-L1
Identifiants
pubmed: 36892210
doi: 10.1002/1878-0261.13415
pmc: PMC10158776
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
737-746Informations de copyright
© 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
Appl Immunohistochem Mol Morphol. 2017 Aug;25(7):453-459
pubmed: 28549039
J Thorac Oncol. 2017 Feb;12(2):208-222
pubmed: 27913228
Int J Mol Sci. 2021 Jun 29;22(13):
pubmed: 34209696
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Cancer Med. 2018 Dec;7(12):5910-5919
pubmed: 30565869
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Pathol Res Pract. 2022 May;233:153893
pubmed: 35429890
JAMA Oncol. 2019 Dec 1;5(12):1749-1768
pubmed: 31560378
Cancer Cytopathol. 2020 Dec;128(12):928-938
pubmed: 32721105
Cancers (Basel). 2020 Feb 13;12(2):
pubmed: 32069934
Diagnostics (Basel). 2021 Oct 18;11(10):
pubmed: 34679625
Int J Cancer. 2016 Jun 15;138(12):2894-904
pubmed: 26789903
Appl Immunohistochem Mol Morphol. 2018 Nov/Dec;26(10):701-708
pubmed: 30095468
Clin Chem. 2016 Nov;62(11):1504-1515
pubmed: 27630154
Theranostics. 2021 Jul 6;11(16):8057-8075
pubmed: 34335980
Acta Cytol. 2021;65(6):501-509
pubmed: 34233336
Virchows Arch. 2020 Feb;476(2):261-271
pubmed: 31392467
Mol Cancer. 2020 Jan 24;19(1):15
pubmed: 31980023
Cancers (Basel). 2019 Mar 18;11(3):
pubmed: 30889898
Appl Immunohistochem Mol Morphol. 2015 Sep;23(8):541-9
pubmed: 26317305
Lung Cancer. 2018 Jun;120:108-112
pubmed: 29748004
Cancers (Basel). 2021 Apr 09;13(8):
pubmed: 33918661
Cancer Cytopathol. 2019 Feb;127(1):52-61
pubmed: 30500997
Clin Chem. 2021 Mar 31;67(4):631-641
pubmed: 33491069
J Am Soc Cytopathol. 2018 Nov - Dec;7(6):324-332
pubmed: 31043303
Acta Cytol. 2020;64(6):577-587
pubmed: 32599583
Clin Chem. 2021 Nov 01;67(11):1503-1512
pubmed: 34355741
Cancer Cytopathol. 2018 May;126(5):342-352
pubmed: 29499101
Diagn Cytopathol. 2020 Apr;48(4):291-299
pubmed: 31930724
Cancer Cytopathol. 2021 Apr;129(4):304-317
pubmed: 33108706
Biomark Res. 2020 Aug 26;8:34
pubmed: 32864131
Cancers (Basel). 2019 Jun 17;11(6):
pubmed: 31212989
Mol Cancer. 2018 Aug 23;17(1):129
pubmed: 30139382
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Mayo Clin Proc. 2019 Aug;94(8):1623-1640
pubmed: 31378236
J Clin Oncol. 2021 Jul 20;39(21):2339-2349
pubmed: 33872070
Ann Oncol. 2018 Jan 1;29(1):193-199
pubmed: 29361135
JAMA Oncol. 2016 Jan;2(1):46-54
pubmed: 26562159
Acta Cytol. 2020;64(1-2):16-29
pubmed: 30878997
J Exp Med. 2017 Apr 3;214(4):895-904
pubmed: 28302645
BMC Cancer. 2019 Jun 7;19(1):546
pubmed: 31174496